Stocktoria
Evolus, Inc. EOLS
Nasdaq · XNAS · stock · Pharmaceutical Preparations · website · IPO 2018-02-08
Evolus, Inc. financials (annual, from 10-K)
| Metric | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 |
|---|---|---|---|---|---|
| Revenue | $297.2M | $266.3M | $202.1M | $148.6M | $99.7M |
| Gross profit | $197.1M | $182.3M | $137.6M | $89.8M | — |
| R&D expense | — | — | — | — | $2.1M |
| SG&A expense | $220.8M | $198.0M | $164.9M | $141.8M | $112.1M |
| Operating income | -$32.7M | -$34.4M | -$49.2M | -$65.3M | -$44.4M |
| Interest expense | — | — | $13.8M | $9.1M | $1.4M |
| Income tax | $677,000 | $664,000 | $176,000 | $95,000 | $42,000 |
| Net income | -$51.6M | -$50.4M | -$61.7M | -$74.4M | -$46.8M |
| EPS (diluted) | $-0.80 | $-0.81 | $-1.08 | $-1.33 | $-0.94 |
| Operating cash flow | -$42.3M | -$18.0M | -$34.0M | -$84.9M | -$33.4M |
| Free cash flow | -$45.7M | -$19.5M | -$34.5M | -$86.5M | -$33.8M |
| Cash & equivalents | $53.8M | $87.0M | $62.8M | $53.9M | $146.3M |
| Inventory | $27.0M | $12.2M | $11.0M | $18.9M | $1.8M |
| Total assets | $225.9M | $232.6M | $189.0M | $178.0M | $257.5M |
| Total liabilities | $249.0M | $227.0M | $209.7M | $159.5M | $175.6M |
| Shareholders' equity | -$23.1M | $5.5M | -$20.7M | $18.5M | $81.9M |
Source: SEC EDGAR filings · CIK 0001570562 · as of 2025-12-31. Facts from filings plus Stocktoria's own computed scores — not investment advice.